Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

SISCAPA Assay Technologies Appoints Gustavo Salem as President and CEO

Published: Monday, April 28, 2014
Last Updated: Tuesday, April 29, 2014
Bookmark and Share
Gustavo has previously worked worked closely with the company to evaluate strategic opportunities in life science research.

SISCAPA Assay Technologies, Inc. today announced the appointment of Gustavo (Gus) Salem to the position of President and CEO.  For the past 18 months, Gus has served as a member of the board of directors and has worked closely with the company to evaluate strategic opportunities in the life science research and clinical diagnostics markets.

“We are extremely pleased to have Gus join the SAT team, and to drive our execution as a commercial stage company,” said Leigh Anderson, SAT’s founder, who continues as Chairman and Chief Scientific Officer.  “Gus has already brought great value as an engaged board member based on a proven track-record in building teams, developing strategy and entering new markets.  His familiarity with the company, technology and team will provide for a smooth and effective transition.”

Gus brings over 25 years of life science and health science leadership experience to the position. Previously, while VP and General Manager of the Biological Systems Division at Agilent Technologies, he managed the mass spectrometry, genomics, and clinical diagnostics businesses amounting to >$500M annual sales. During his tenure, Agilent developed into a market-leading supplier of LC/MS and established market leadership in target enrichment sample prep for next generation DNA sequencing. Gus previously served as President and CEO of Assay Designs, Inc., a venture-backed company developing immunoassays and antibody reagents (now part of Enzo Life Sciences). Prior to Assay Designs he managed the Protein Separations Division of Bio-Rad Laboratories, which included product lines for chromatography and electrophoresis instruments and consumables.

“I want to thank Leigh and my fellow board members for this opportunity.  We have identified some very exciting new diagnostic opportunities, and will continue to invest in the analytical and clinical validation of SISCAPA technology.  The company is committed to our current partners and customers in improving access to the technology, and expanding our customer base through launch of new products and services,” said Mr. Salem.  “I am very excited to lead the team as we increase our focus on lab operations and commercial activities.  We have great partners, strong revenue momentum, and an excellent strategy focused on empowering patients through improved clinical tests.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SISCAPA Assay Technologies Closes Series A Financing Round
The company will now move forward on targeting wellness and chronic disease monitoring.
Monday, May 12, 2014
Scientific News
Integrated Omics Analysis
Studying multi-omics promises to give a more holistic picture of the organism and its place in its ecosystem, however despite the complexities involved those within the field are optimistic.
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Alzheimer’s-Linked Protein May Play Role in Schizophrenia
Researchers suggests a protein linked to cognitive decline in Alzheimer's also plays a role in genetic predisposition to schizophrenia.
Peptides vs. Superbugs
Scientists successfully develop a shuttle system made of liquid-crystalline nanomaterials that protect peptites.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Immune Approach Targets Humans Instead of Bacteria
Scientists show for the first time how bacterial superantigen toxins work, and how short peptides can block them and save lives.
Could 2D Mass Spec Breakthrough Lead to Medical Revolution?
Pharmaceutical research could be quicker and more precise, thanks to an innovative breakthrough in 2D mass spec from the University of Warwick.
Less is More in Ribosome Assembly
Research uncovers genetic "program" that allows for ribosome formation with a limited supply of magnesium.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos